Prediction of in vitro metabolic stability of calcitriol analogs by QSAR

The metabolic stability of a drug is an important property for potential drug candidates. Measuring this property, however, can be costly and time-consuming. The use of quantitative structure-activity relationships (QSAR) to estimate the in vitro stability is an attractive alternative to experimental measurements. A data set of 130 calcitriol analogs with known values of in vitro metabolic stability was used to develop QSAR models. The analogs were encoded with molecular structure descriptors computed mainly with the commercial software QikProp and DiverseSolutions. Variable selection was carried out by five different variable selection techniques and Partial Least Squares Regression (PLS) models were generated from the 130 analogs. The models were used for prediction of the metabolic stability of 244 virtual calcitriol analogs. Twenty of the 244 analogs were selected and the in vitro metabolic stability was determined experimentally. The PLS models were able to predict the correct metabolic stability for 17 of the 20 selected analogs, corresponding to a prediction performance of 85%. The results clearly demonstrate the utility of QSAR models in predicting the in vitro metabolic stability of calcitriol analogs.

[1]  W. C. Still,et al.  The GB/SA Continuum Model for Solvation. A Fast Analytical Method for the Calculation of Approximate Born Radii , 1997 .

[2]  C. Hansch,et al.  p-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure , 1964 .

[3]  T. Halgren.  MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular‐interaction energies and geometries , 1999, Journal of computational chemistry.

[4]  S. Ekins,et al.  Progress in predicting human ADME parameters in silico. , 2000, Journal of pharmacological and toxicological methods.

[5]  G. V. D. van den Bemd,et al.  Vitamin D and vitamin D analogs in cancer treatment. , 2002, Current drug targets.

[6]  T. Halgren.  MMFF VI. MMFF94s option for energy minimization studies , 1999, J. Comput. Chem..

[7]  S. Wold.  Cross-Validatory Estimation of the Number of Components in Factor and Principal Components Models , 1978 .

[8]  E. V. Thomas,et al.  Partial least-squares methods for spectral analyses. 1. Relation to other quantitative calibration methods and the extraction of qualitative information , 1988 .

[9]  F. Dilworth,et al.  Increased biological activity of 20-epi-1,25-dihydroxyvitamin D3 is due to reduced catabolism and altered protein binding. , 1994, Biochemical pharmacology.

[10]  F. Burden.  Molecular identification number for substructure searches , 1989, J. Chem. Inf. Comput. Sci..

[11]  Peter C. Jurs,et al.  Prediction of Human Intestinal Absorption of Drug Compounds from Molecular Structure , 1998, J. Chem. Inf. Comput. Sci..

[12]  Agnar Höskuldsson,et al.  The H-principle: New ideas, algorithms and methods in applied mathematics and statistics , 1994 .

[13]  H. Martens,et al.  Modified Jack-knife estimation of parameter uncertainty in bilinear modelling by partial least squares regression (PLSR) , 2000 .

[14]  John H. Holland,et al.  Adaptation in Natural and Artificial Systems: An Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence , 1992 .

[15]  S. Engelsen,et al.  Interval Partial Least-Squares Regression (iPLS): A Comparative Chemometric Study with an Example from Near-Infrared Spectroscopy , 2000 .

[16]  E. Abe,et al.  Functional defect of variant clones of a human myeloid leukemia cell line (HL-60) resistant to 1 alpha,25-dihydroxyvitamin D3. , 1983, Endocrinology.

[17]  John G. Topliss,et al.  QSAR Model for Drug Human Oral Bioavailability1 , 2000 .

[18]  S. Krane,et al.  Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. , 1983, The Journal of clinical endocrinology and metabolism.

[19]  J. Stewart.  Optimization of parameters for semiempirical methods I. Method , 1989 .

[20]  S. Venkatesh,et al.  Role of the development scientist in compound lead selection and optimization. , 2000, Journal of pharmaceutical sciences.

[21]  John H. Kalivas,et al.  Comparison of Forward Selection, Backward Elimination, and Generalized Simulated Annealing for Variable Selection , 1993 .

[22]  G. Cruciani,et al.  Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems , 1993 .

[23]  G. Cruciani,et al.  Predictive ability of regression models. Part II: Selection of the best predictive PLS model , 1992 .

[24]  A. Kissmeyer,et al.  Pharmacokinetics and metabolism of a vitamin D analogue (Seocalcitol) in rat and minipig , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[25]  T N Thompson,et al.  Optimization of metabolic stability as a goal of modern drug design , 2001, Medicinal research reviews.

[26]  J. Ponder,et al.  An efficient newton‐like method for molecular mechanics energy minimization of large molecules , 1987 .

[27]  M. Sar,et al.  Topographical and developmental studies on target sites of 1,25 (OH2) vitamin D3 in skin , 2004, Cell and Tissue Research.

[28]  S. Manolagas,et al.  1 alpha,25-Dihydroxyvitamin D3-binding macromolecules in human B lymphocytes: effects on immunoglobulin production. , 1986, Journal of immunology.

[29]  Panos Macheras,et al.  In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. , 2002, European Journal of Pharmaceutical Sciences.